Last reviewed · How we verify
Placebo Tablet and Placebo Patch
Placebo Tablet and Placebo Patch is a Small molecule drug developed by The Scripps Research Institute. It is currently FDA-approved for Clinical trial control comparator (non-therapeutic use).
Placebo formulations contain no active pharmaceutical ingredient and produce therapeutic effects solely through the placebo effect.
Placebo Tablet and Placebo Patch are inert substances used as controls in clinical trials, with the Placebo Patch being a transdermal delivery system. They are small molecule substances, used as comparators in studies for conditions such as Relapsing Multiple Sclerosis, Smoking Cessation, and Multiple Primary Lung Cancers.
At a glance
| Generic name | Placebo Tablet and Placebo Patch |
|---|---|
| Sponsor | The Scripps Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo tablets and patches are inert formulations used as control comparators in clinical trials to measure the effect of patient expectation and the therapeutic ritual independent of any pharmacological action. They allow researchers to distinguish between the true drug effect and the psychological/physiological response to receiving treatment. Placebos are essential tools in randomized controlled trials to establish efficacy and safety of investigational drugs.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
- Placebo effect (symptom improvement without active ingredient)
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms
- Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy (PHASE1, PHASE2)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Reward Sensitivity and Pharmacotherapy for Smoking Cessation (PHASE4)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Tablet and Placebo Patch CI brief — competitive landscape report
- Placebo Tablet and Placebo Patch updates RSS · CI watch RSS
- The Scripps Research Institute portfolio CI
Frequently asked questions about Placebo Tablet and Placebo Patch
What is Placebo Tablet and Placebo Patch?
How does Placebo Tablet and Placebo Patch work?
What is Placebo Tablet and Placebo Patch used for?
Who makes Placebo Tablet and Placebo Patch?
What development phase is Placebo Tablet and Placebo Patch in?
What are the side effects of Placebo Tablet and Placebo Patch?
Related
- Manufacturer: The Scripps Research Institute — full pipeline
- Indication: Drugs for Clinical trial control comparator (non-therapeutic use)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing